1-6 of 6
James B. Lorens
Close
Sort by
Journal Articles

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Sonja Loges, Grerk Sutamtewagul, Michael Heuser, Jörg Chromik, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele Giovanni Mattei, Isabel Ben Batalla, Monica Hellesøy, Jonas Waizenegger, Melanie Janning, Charles D. Imbusch, Niklas Beumer, Austin Rayford, Jaya Nautiyal, Tzivia Berkman-Gottlieb, David Micklem, Hani Gabra, Claudia Gorcea-Carson, James B. Lorens, Walter Fiedler, Yesid Alvarado, Bjorn T. Gjertsen, Lisa-Marie Rieckmann
Journal: Blood
Blood (2021) 138 (Supplement 1): 3410.
https://doi.org/10.1182/blood-2021-147225
Published: 2021
Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Sonja Loges, MD PhD, Michael Heuser, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, MD, Nicola Di Renzo, MD, Roberto M. Lemoli, Daniele Giovanni Mattei, MD, Isabel Ben-Batalla, PhD, Monica Hellesoy, PhD, Katherine Lorens, MD, Joseph Birkett, PhD, Stuart McPherson, BSc, Jaya Nautiyal, PhD, David Micklem, PhD, Hani Gabra, MD PhD FRCPE, FRCP, James B. Lorens, PhD, Walter Fiedler, MD, Yesid Alvarado, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14.
https://doi.org/10.1182/blood-2020-136566
Published: 2020
Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Sonja Loges, MD, PhD, Michael Heuser, MD, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, Nicola Di Renzo, MD, Roberto Massimo Lemoli, MD, Daniele Giovanni Mattei, MD, Isabel Ben Batalla, PhD, Monica Hellesoy, PhD, David Micklem, PhD, Robert J. Holt, PhD, James B. Lorens, PhD, Muhammad Shoaib, MD, Hassan Aly, MD PhD, Wouter Hanekom, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3943.
https://doi.org/10.1182/blood-2019-128683
Published: 2019
Journal Articles

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

Isabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, Robert Erdmann, Michael Heuser, Jonas S. Waizenegger, Kristoffer Riecken, Mascha Binder, Denis Schewe, Stefanie Sawall, Victoria Witzke, Miguel Cubas-Cordova, Melanie Janning, Jasmin Wellbrock, Boris Fehse, Christian Hagel, Jürgen Krauter, Arnold Ganser, James B. Lorens, Walter Fiedler, Peter Carmeliet, Klaus Pantel, Carsten Bokemeyer, Sonja Loges
Journal: Blood
Blood (2013) 122 (14): 2443–2452.
https://doi.org/10.1182/blood-2013-03-491431
Published: 2013
Includes: Supplemental data
Journal Articles

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

Francesco Parlati, Susan J. Lee, Monette Aujay, Erika Suzuki, Konstantin Levitsky, James B. Lorens, David R. Micklem, Paulina Ruurs, Catherine Sylvain, Yan Lu, Kevin D. Shenk, Mark K. Bennett
Journal: Blood
Blood (2009) 114 (16): 3439–3447.
https://doi.org/10.1182/blood-2009-05-223677
Published: 2009
Includes: Supplemental data
Journal Articles

Bcl-2 Protects against p53-Induced Apoptosis through Hdm2

Line Wergeland, Kevin B. Spurgers, Eystein Oveland, Torill Høiby, Manel Cascallo, Tsuyoshi Honda, James B. Lorens, Guillermina Lozano, Timothy J. McDonnell, MD, PhD, Bjorn T. Gjertsen, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 5333.
https://doi.org/10.1182/blood.V112.11.5333.5333
Published: 2008